124 related articles for article (PubMed ID: 22337220)
1. Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.
Maron BA; Bhatt DL; Nykiel M; Kinlay S; Waxman AB
Crit Pathw Cardiol; 2012 Mar; 11(1):40-2. PubMed ID: 22337220
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
[TBL] [Abstract][Full Text] [Related]
3. Role of Vasodilator Testing in Pulmonary Hypertension.
Sharma A; Obiagwu C; Mezue K; Garg A; Mukherjee D; Haythe J; Shetty V; Einstein AJ
Prog Cardiovasc Dis; 2016; 58(4):425-33. PubMed ID: 26434988
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
5. [Hemodynamic study: indications for right- and left-sided catheterization in the diagnosis and follow-up of pulmonary hypertension].
Amaro Cendón A
Arch Bronconeumol; 2011; 47 Suppl 7():12-4. PubMed ID: 23351470
[TBL] [Abstract][Full Text] [Related]
6. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
7. [How to do vasoreactivity test?].
Canpolat U; Kaya EB
Turk Kardiyol Dern Ars; 2012 Jun; 40(4):386-9. PubMed ID: 22951858
[No Abstract] [Full Text] [Related]
8. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.
Buckley MS; Feldman JP
Pharmacotherapy; 2010 Jul; 30(7):728-40. PubMed ID: 20575636
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
10. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
11. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
Klings ES; Hill NS; Ieong MH; Simms RW; Korn JH; Farber HW
Arthritis Rheum; 1999 Dec; 42(12):2638-45. PubMed ID: 10616012
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 across the lung circulation in patients with pulmonary arterial hypertension and influence of epoprostenol infusion.
Selimovic N; Andersson B; Bergh CH; Sakiniene E; Carlsten H; Rundqvist B
J Heart Lung Transplant; 2009 Aug; 28(8):808-14. PubMed ID: 19632577
[TBL] [Abstract][Full Text] [Related]
13. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Apitz C; Hansmann G; Schranz D
Heart; 2016 May; 102 Suppl 2():ii23-9. PubMed ID: 27053694
[TBL] [Abstract][Full Text] [Related]
15. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.
Haché M; Denault A; Bélisle S; Robitaille D; Couture P; Sheridan P; Pellerin M; Babin D; Noël N; Guertin MC; Martineau R; Dupuis J
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):642-9. PubMed ID: 12658208
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
Bildirici I; Shumway JB
Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
[TBL] [Abstract][Full Text] [Related]
17. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
18. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
19. Inhaled prostacyclin following surgical repair of congenital heart disease--a pilot study.
Carroll CL; Backer CL; Mavroudis C; Cook K; Goodman DM
J Card Surg; 2005; 20(5):436-9. PubMed ID: 16153274
[TBL] [Abstract][Full Text] [Related]
20. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
Barst R
Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
